Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study

Muris, Anne-Hilde; Smolders, Joost; Rolf, Linda; Thewissen, Mariëlle; Hupperts, Raymond; Damoiseaux, Jan

doi:10.1016/j.jneuroim.2016.09.018

Cited by 82 publications

(96 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the above studies reported encouraging results, four studies in this review showed results that were not as positive (O'Connell et al, 2017;Holmoy et al, 2017;Muris et al, 2016b;Rosjo et al, 20115). Holmoy et al (2017) and Rosjo et al (2015) examined bone health in RRMS patients who received 20,000 IU D3 weekly over 96 weeks.…”

Section: Discussionmentioning

confidence: 66%

“…They advised that young MS patients should be given vitamin D3 supplements as a preventative option. Muris et al (2016b) investigated the effects of highdose vitamin supplementation on a group of 30 Dutch RRMS patients who had been treated with IFNβ-1 while 23 patients got a placebo. They found that the number of cells in the immune regulatory compartment remained unaltered when patients were given a high dose of vitamin D3.…”

Section: Resultsmentioning

confidence: 99%

“…This group admitted that further study is needed in this area. One study looked at changes in immune regulatory parameters and after 48 weeks, there was no increase in lymphocytes with a regulatory phenotype (Muris et al, 2016b). However, the group believes the results support the hypothesis that D3 contributes to maintenance of immune homeostasis by preventing further disturbance of the T cell compartment early in the disease course of MS.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

High-Dose Vitamin D3 Intake Is Associated with Decreased Symptoms of Multiple Sclerosis

Steinwart¹,

Duriancik²

2018

American Journal of Immunology

View full text Add to dashboard Cite

Multiple sclerosis (MS) is one of the most widespread disabling autoimmune neurological conditions of adults between the ages of 20 and 40 globally. Medical researchers do not completely understand the possible causes of MS, nor have they determined the rate of progression. A limited number of clinical trials conducted in recent years have explored the link between vitamin D deficiency and MS with vitamin D supplementation as a possible element in the treatment of this disease. The primary goal of this review was to synthesize the evidence regarding the link between vitamin D3 levels and the symptoms of MS. A PubMed search was conducted using keywords Vitamin D, multiple sclerosis, MS, RRMS, prevention, treatment and cause. 1153 articles and sources were found using the key phrase "multiple sclerosis and vitamin D," but these were narrowed to 11 based on publication dates between 2013 and 2018, clinical trials were included, while reviews were excluded and the relevance of the goals to this review. Study designs included experimental clinical trials where pretest/posttest data were presented. Articles were excluded if they were not peer reviewed or only described the method and were awaiting results. Although not all studies found uniform results, the majority of the evidence suggests that high intakes of vitamin D may be associated with improved quality of life through the reduction of certain symptoms of MS. This was especially evident in patients who started the studies with a vitamin D deficiency. It may be too early to prescribe an increase in daily supplementation of vitamin D with the hope of reducing the development of or in the treatment of MS, but recent studies indicate that high doses of vitamin D could decrease the probability of some symptoms of the disease and possibly give favorable results in treatment. Further studies are needed before specific recommendations can be made.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High-Dose Vitamin D3 Intake Is Associated with Decreased Symptoms of Multiple Sclerosis

Steinwart¹,

Duriancik²

2018

American Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Similarly, a sub-study of a larger clinical trial exploring high dose (up to 14,000 IU/day) vitamin D supplementation, as an add-on therapy to interferon beta 1a in patients with RRMS, showed no difference in either IL-17 CD4+ or IFNgamma CD4+ T cells at 48 weeks of observation [48].…”

Section: Cd4+ T Cellsmentioning

confidence: 98%

Vitamin D as an immune modulator in multiple sclerosis

Bartosik-Psujek

Psujek

2019

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the central nervous system. The disease is characterised by inflammation with extensive immune infiltration, demyelination, axonal loss and damage of oligodendrocytes, presumably auto-immune in nature. The influence of environmental factors on the development and activity of MS has been known for a long time. Vitamin D and sun exposure are among the most important ones. Both serum vitamin D level and sun exposure independent of vitamin D production are correlated with epidemiological and clinical parameters of MS, and the impact of vitamin D on immune parameters has been clearly confirmed in experimental studies. Nevertheless, the impact on clinical aspects is inconclusive, especially when the influence of supplementation is assessed. In this work we review the state of knowledge regarding the effect of vitamin D on immune cells subsets in relation to experimental and clinical studies.

show abstract

“…5 The deficiency of serum 25-hydroxyvitamin D (25[OH]D) is one of the underlying causes of a variety of disorders, including coronary artery disease, arrhythmias, neurological diseases, and cancers. [6][7][8][9] So far, there have been a large number of studies in the literature analysing the association of serum 25[OH]D and cardiovascular autonomic dysfunction, but studies involving the evaluation of the syncope with HUTT are very limited. [10][11][12] In our study, we aimed to compare serum 25[OH]D levels between patients with VVS diagnosed with HUTT and age-matched healthy people.…”

Section: Introductionmentioning

confidence: 99%

Is there any link between vitamin D deficiency and vasovagal syncope?

Usalp

Kemal

Yüksek

et al. 2020

Journal of Arrhythmia

View full text Add to dashboard Cite

Background This study aimed to investigate serum 25[OH]D levels between patients with vasovagal syncope (VVS) diagnosed with head‐up tilt table test (HUTT) and age‐matched healthy people. Methods The study included 75 consecutive patients (32.3 ± 10.7 years), who presented with syncope and underwent HUTT and 52 healthy controls (32.9 ± 14.1 years). HUTT patients were divided into two groups according to whether there was syncope response to the test. Patients underwent cardiac, psychiatric, and neurological investigation. Serum 25[OH]D levels were measured by chemiluminescent microparticle immunoassay method. Results There was no difference between the two groups in terms of age, gender, body mass index (BMI), echocardiographic findings (P > .05). Mean serum 25[OH]D (24.5 ± 6.3 vs 20.1 ± 8.8 ng/mL, P = .003) and vitamin B12 levels (436.4 ± 199.2 vs 363.1 ± 107.6 pg/mL, P = .009) was lower in syncope patients when compared to the control group. In correlation analyses, syncope was shown as correlated with the vitamin D (r = −264, P = .003) and vitamin B12 levels (r = −233, P = .009). But, multivariate regression analyses showed that only vitamin D increased risk of syncope [OR: 0.946, 95% CI (0.901‐0.994)]. There was no difference in terms of age, gender, BMI, echocardiographic findings between the in HUTT positive (n = 45) and negative groups (n = 29). Only vitamin D level was significantly lower in HUTT positive group (17.5 ± 7.7 vs 24.4 ± 9.1 ng/mL, P = .002). There was no difference among in the vasovagal subgroups in terms of vitamin D level and other features. Conclusion Vitamin D and B12 levels were reasonably low in syncope patients, but especially low Vitamin D levels were associated with VVS diagnosed in HUTT.

show abstract

Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study

Cited by 82 publications

References 55 publications

High-Dose Vitamin D3 Intake Is Associated with Decreased Symptoms of Multiple Sclerosis

High-Dose Vitamin D3 Intake Is Associated with Decreased Symptoms of Multiple Sclerosis

Vitamin D as an immune modulator in multiple sclerosis

Is there any link between vitamin D deficiency and vasovagal syncope?

Contact Info

Product

Resources

About